Drug discovery

#Antibodies #Antibody libraries #Biologics #Biopharmaceuticals #DNA #Drug discovery #Drug targets #Screening

Newly launched antibody libraries put hard-to-drug targets within reach

Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates. Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Collaboration #Drug discovery

This week in drug discovery (8-12 November) 

News round-up by DDW’s Megan Thomas for 8-12 November  DDW’s Megan Thomas has selected five stories which highlight the collaborative work being done across the drug discovery industry.  1. SAGA Diagnostics and AstraZeneca enter assay development agreement  SAGA Diagnostics, a cancer liquid… Read More

#News #Trending News

#Covid-19 #Drug design #Drug discovery #Immunology / Virology & Vaccines #Research #T-Cells

T-cell discovery could lead to new type of Covid-19 vaccines 

A study has found that some people are able to clear the Covid-19 virus quickly due to strong immune response from existing T-cells, which could lead to a new generation of vaccine development.   In a study published in Nature, researchers found that individuals with potential exposure to… Read More

#Covid-19 #News #Trending News

#Biochemistry #Drug discovery #Drug targets #Mass spectrometry / NMR #Small molecules #Therapeutics

OMass unveils drug discovery pipeline for validated targets 

OMass Therapeutics has shared its pipeline of five novel, differentiated small molecule drug programmes, targeting intractable or inadequately drugged membrane and complex-bound protein targets such as GPCRs (G-protein-coupled receptors), solute carriers and intracellular protein complexes.  The company’s selected programmes focus on validated targets in immunology & rare disease indications with high unmet need. Read More

#News

#Cell and gene therapy #Cell therapy #Drug discovery #Funding

bit.bio receives $103 million for human cell production  

Human cell coding company bit.bio has closed a Series B financing of $103 million to accelerate the clinical development of the company’s cell coding technology opti-oxTM, a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells. … Read More

#News

#Biology #Data #Drug discovery #Metabolomics #Precision medicine #Research

New metabolomics solution enables understanding of the microbiome 

Metabolon’s first offering from its SmartPanel portfolio aims to provide drug discovery and precision medicine researchers with a novel, dynamic process to explore biologically relevant views of metabolomic data in the context of specific metabolic pathways, biological themes, and disease associations.  “The metabolome offers a window into human… Read More

#Editor's Choice #News #Trending News

Seed funding
#Drug discovery #Research

Acquisition to create breakthrough approach for clinical trials 

THREAD has acquired Modus Outcomes to combine high-technology and high-science in one platform designed to achieve higher-quality outcomes for research sponsors.   As clinical trials have grown more complex, so has effectively designing and implementing endpoints, which are now required in most research studies. With this acquisition, THREAD… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Drug discovery

AI acquisition accelerates outcomes in early drug discovery 

X-Chem has announced the acquisition of Glamorous AI, combining X-Chem’s DNA-encoded library (DEL) data with the AI capabilities of Glamorous AI. This reportedly positions X-Chem as a leading service provider in machine learning-driven drug discovery.  “What AlphaFold did for protein folding, X-Chem and Glamorous AI will do for drug… Read More

#News

#Antibodies #Collaboration #Drug development #Drug discovery #Monoclonal antibodies

Nautilus and Abcam partner to accelerate proteome exploration  

Nautilus Biotechnology and Abcam have announced a strategic development and supply partnership to leverage Abcam’s recombinant monoclonal antibody development technologies and expertise to enhance Nautilus’ reagent research and development.   The partnership will initially focus on the collaborative development of affinity binding reagents for use on the… Read More

#News #Trending News

#Biotechnology #Case study #Drug discovery #High throughput screening

Case study: Discover an innovative CRO offering unique solutions

Drug discovery contract research organizations (CROs) offer an established infrastructure and experience that offers promising paths forward for various research projects. However, partnering with a CRO also presents key challenges, and companies should consider three questions: How long until data is delivered? Will the quality of the data instill confidence… Read More

#News

#CAR-T #Cell and gene therapy #Collaboration #Drug development #Drug discovery

Sitting down with… Julian Cole, Cell & Gene Collective 

The Cell & Gene Collective publicly launched in May 2021. Lu Rahman caught up with Julian Cole, Country Medical Director of Gilead Sciences for the UK and Ireland to find out more about this cross-industry alliance between Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis. Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Drug discovery #Neuroscience #Psychedelics

Experienced neuroscientist joins Beckley Psytech as CMO 

Beckley Psytech, a clinical stage, biotechnology company dedicated to addressing neuropsychiatric disorders through the novel application of psychedelic medicines, has appointed Frank Wiegand as Chief Medical Officer.  Dr. Wiegand, a trained neurologist and neuroscientist, joins Beckley Psytech after more than 20 years with Janssen (a Johnson & Johnson company), where… Read More

#News

#Drug discovery #High content imaging #Imaging #Podcast

Podcast: Analysing the technology driving innovation in drug discovery

The latest free-to-listen DDW podcast episode is titled “Analysing the technology driving innovation in drug discovery”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine, narrated by DDW’s Megan Thomas.  These articles are titled: “How imaging techniques… Read More

#Editor's Choice #News

#Alzheimer's #Drug discovery #Genetics #Life sciences #Neuroscience #Therapeutics

Is new thinking the key to unlocking Alzheimer’s treatment?

Professor Paul Whiting, Chief Scientific Officer of The Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI), and Stephane Martinez, product manager and neuroscience expert in PerkinElmer’s Life Sciences segment, share expert insights on Alzheimer’s Disease research today and where discovery and therapeutic approaches might be headed next. Read More

#Editor's Choice #News #Opinion

#Drug development #Drug discovery #Funding #Therapeutics

Researchers awarded $12 million for personalised asthma therapies

A group of researchers led by Indiana University School of Medicine’s Benjamin Gaston has been awarded a research programme project grant from the National Heart, Lung and Blood Institute. The award amounts to just over $12 million over the next five years and will fund the development of personalised… Read More

#News

#AI #Drug development #Drug discovery #Machine learning #Therapeutics

Why we are on the cusp of a golden age of medicine 

Listen to this article on the DDW Podcast:   Panna Sharma is the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics. Lu Rahman spoke to the man behind this biotech to find… Read More

#Cancer Research #Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis